RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

This study is testing a drug called RC48 — a targeted therapy that delivers chemotherapy directly to cancer cells expressing HER2 — for women with ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based chemotherapy. **You may be eligible if...** - You are a woman aged 18–75 with confirmed ovarian, fallopian tube, or peritoneal cancer - Your cancer has come back after prior platinum-based chemotherapy - You have received 1–4 prior lines of treatment - Your cancer tests positive for HER2 (IHC 1+, 2+, or 3+) - You are in reasonably good health (ECOG 0–1) with measurable cancer on imaging **You may NOT be eligible if...** - You have previously received HER2-targeted therapy - You have very poor overall health or organ function - You are pregnant or breastfeeding - Your cancer is not measurable on imaging Talk to your doctor to see if this trial is right for you.